Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight. / DeBenedictis, Julia Nicole; Nymo, Siren; Ollestad, Karoline Haagensli; Boyesen, Guro Akersveen; Rehfeld, Jens Frederik; Holst, Jens Juul; Truby, Helen; Kulseng, Bard; Martins, Catia.
In: Journal of Clinical Endocrinology & Metabolism, Vol. 105, No. 7, 2020, p. e2538-e2546.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight
AU - DeBenedictis, Julia Nicole
AU - Nymo, Siren
AU - Ollestad, Karoline Haagensli
AU - Boyesen, Guro Akersveen
AU - Rehfeld, Jens Frederik
AU - Holst, Jens Juul
AU - Truby, Helen
AU - Kulseng, Bard
AU - Martins, Catia
PY - 2020
Y1 - 2020
N2 - Objective: To compare appetite markers in reduced-obese individuals with a nonobese control group.Methods: A total of 34 adults with obesity who lost 17% body weight at week 13 and maintained this weight loss (WL) at 1 year were compared with 33 nonobese controls matched for body composition. Basal and postprandial subjective appetite ratings and appetite-related hormone concentrations (ghrelin, total peptide YY, peptide YY3-36, total and active glucagon-like peptide 1, and cholecystokinin) were measured in all participants and repeated at week 13 and 1 year in the weight-reduced group.Results: WL led to a reduction in prospective food consumption and an increase in feelings of hunger, fullness, and ghrelin secretion (basal and postprandial), but these new ratings were no different from those seen in controls. Postprandial concentrations of active glucagon-like peptide 1, total peptide YY, and cholecystokinin were lower in individuals with obesity at all time points compared with controls.Conclusion: The increased drive to eat (both subjective feelings of hunger and ghrelin concentrations) seen in reduced-obese individuals, both after acute and sustained WL, reflects a normalization toward a lower body weight. Overall, WL does not have a sustained negative impact on satiety peptide secretion, despite a blunted secretion in individuals with obesity compared with nonobese controls.
AB - Objective: To compare appetite markers in reduced-obese individuals with a nonobese control group.Methods: A total of 34 adults with obesity who lost 17% body weight at week 13 and maintained this weight loss (WL) at 1 year were compared with 33 nonobese controls matched for body composition. Basal and postprandial subjective appetite ratings and appetite-related hormone concentrations (ghrelin, total peptide YY, peptide YY3-36, total and active glucagon-like peptide 1, and cholecystokinin) were measured in all participants and repeated at week 13 and 1 year in the weight-reduced group.Results: WL led to a reduction in prospective food consumption and an increase in feelings of hunger, fullness, and ghrelin secretion (basal and postprandial), but these new ratings were no different from those seen in controls. Postprandial concentrations of active glucagon-like peptide 1, total peptide YY, and cholecystokinin were lower in individuals with obesity at all time points compared with controls.Conclusion: The increased drive to eat (both subjective feelings of hunger and ghrelin concentrations) seen in reduced-obese individuals, both after acute and sustained WL, reflects a normalization toward a lower body weight. Overall, WL does not have a sustained negative impact on satiety peptide secretion, despite a blunted secretion in individuals with obesity compared with nonobese controls.
KW - weight loss
KW - normalization
KW - compensation
KW - ghrelin
KW - hunger
KW - GLUCAGON-LIKE PEPTIDE-1
KW - ENERGY-INTAKE
KW - LOSS MAINTENANCE
KW - OBESE
KW - TERM
KW - CHOLECYSTOKININ
KW - GHRELIN
KW - INSULIN
KW - ADULTS
KW - REGAIN
U2 - 10.1210/clinem/dgaa202
DO - 10.1210/clinem/dgaa202
M3 - Journal article
C2 - 32301981
VL - 105
SP - e2538-e2546
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 7
ER -
ID: 250120352